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Case RepoRt
Immune hemolytic anemia (IHA) is a rare complication of drug 
administration. However, its true incidence remains obscure, as 
there are a number of factors that may lead to misdiagnosis. The 
clinical and serologic pictures are variable, and there is a great deal 
of unawareness that certain drugs can cause IHA. Furthermore, 
serologic results can be easily misinterpreted, resulting in a 
wrong diagnosis. Immunohematology 2014;30:80–84.
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Although drug-induced immune hemolytic anemia 
(DIIHA) is a well-known complication of drug administration, 
a number of diagnostic pitfalls still occur on the patient’s side, 
at patient bedside, and in laboratories.
The key to a correct diagnosis is a sophisticated history of 
drug administration and sufficient clinical as well as serologic 
experience in this field. As demonstrated in this issue, the list 
of drugs implicated in DIIHA continues to grow, not only by a 
variety of new drugs but also by known drugs. However, some 
published data rely solely on temporal relationships between 
hemolysis and drug administration without confirmation by 
serologic testing. On the other hand, there is evidence that 
DIIHA is far more common than has yet been estimated. 
Ultimately, serologic testing is frequently inadequate or 
even lacking. In addition, some cases remain unrecognized 
or unreported. In this review, we attempt to highlight the 
main errors leading to false diagnosis or a lack of diagnosis. 
To provide clarity to such errors, we first describe a few 
representative cases.
Representative Cases
Cases 1 and 2
A 54-year-old woman was admitted for hematuria and 
anemia. She rapidly recovered during clinical observation, 
presumably as a result of unintended discontinuation of 
all medications. Serologic testing revealed an only C3d-
positive direct antiglobulin test (DAT), and her plasma was 
observed to be reddish. Based on these findings, DIIHA was 
suspected. However, the patient was discharged from the 
hospital without diagnosis. The patient was readmitted on 
the following day with massive hemolysis, thrombocytopenia, 
and shock, and subsequently died because of complications 
resulting from massive hemolysis. From a clinical viewpoint, 
an acute Evans syndrome was initially suggested. However, 
we highly suspected a DIIHA. The patient was revealed 
to have received at irregular intervals antihypertensive 
drugs including nifedipine and a combination of buthiazide, 
reserpine, rescinnamine, raubasine, and potassium chloride. 
After several weeks of uninformative serologic testing, the 
drugs were ingested by a volunteer. Serologic testing in the 
presence of serum samples collected after drug ingestion (ex 
vivo antigen) disclosed the buthiazide as the causative drug.1 
In that study, we also described a second patient (Case 2) who 
received an intramuscular injection containing a drug mixture 
because of a prolapsed disk. The patient later experienced 
shock and renal failure that could not be clinically explained. 
We further suspected DIIHA, but serologic testing was 
unsuccessful, even in the presence of ex vivo antigens of the 
injected drugs. On repeat questioning of the patient several 
months later, she declared that she had ingested nomifensine 
(antidepressant) before the onset of lumbar pain. She had not 
previously declared this owing to feelings of shame because of 
her depression and therapy.
Case 3
A 79-year-old woman had abdominal pain and her urine 
was reddish. Because of suspected hematuria and urinary 
tract infection, treatment with an antibiotic drug was started; 
subsequently her condition abruptly deteriorated, eventually 
resulting in shock. The patient was immediately transferred 
to the hospital, where urosepsis, shock, and hemolysis were 
suspected. A blood sample was referred to our laboratory as all 
crossmatched packed red blood cell (RBC) units were positive 
at the hospital providing treatment. On the basis of this history, 
we suspected DIIHA and advised an immediate transfusion. 
Unfortunately, the patient died, and the question as to which 
drug she had received before the development of abdominal 
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pain and hematuria could not be answered. On further 
investigation, evidence of vitamin E was found in her handbag. 
The drug prescribed from her physician was, we believe, 
harmless, as hemolysis was present before deterioration of her 
condition. In an attempt to determine the causative drug, the 
patient’s belongings were searched and more than 40 drugs 
were found (Fig. 1). Thus, it was impossible to identify the 
causative drug. Similar cases may remain unrecognized either 
owing to DIIHA not being suspected or owing to inadequate 
serologic testing or a lack in its implementation.
Case 4
In 2010, we described a patient with fatal immune 
hemolysis caused by specific antibodies to 5-fluorouracil 
(5-FU).2 The patient had cholangiocarcinoma and was 
receiving chemotherapy including oxaliplatin and 5-FU. 
Before admission, the patient had been repeatedly treated (15 
times) with the same combination of drugs without relevant 
side effects. She experienced fatal hemolysis that was initially 
concealed by a blood transfusion. Furthermore, serologic 
findings (positive antibody screening test and positive C3d-
DAT) were misinterpreted as an in vitro phenomenon caused 
by cold agglutinins. After thorough clinical and serologic 
reinvestigation of the case, it became clear that hemolysis was 
related to drug administration. Initially, oxaliplatin, a drug 
frequently resulting in immune hemolysis, was suspected. 
Only after dialysis of the patient’s serum and intensive 
serologic retesting with several ex vivo metabolites was 5-FU 
determined to be the cause of the hemolysis.
Pitfalls and Limitations
Pitfalls on the Patient’s Side
As described above in our case reports, information 
concerning the patient plays a key role in clinical and serologic 
aspects. The vast majority of patients are not informed about 
symptoms of hemolysis and that drugs may, although rarely, 
result in hemolysis.
The clinical picture of DIIHA is extremely variable, 
and the affected patients are usually unable to recognize a 
relationship between the drugs and secondary symptoms 
of hemolysis, i.e., tachycardia or dyspnea caused by anemia, 
abdominal pain, lumbar pain, and red urine (hemoglobinuria) 
caused by intravascular hemolysis. Depending on the patient’s 
information and the most prominent symptoms, the following 
errors may occur before or after consideration of DIIHA as a 
possible diagnosis:
1. Some patients may recover without further investigations, 
with the diagnosis remaining unclear.
2. Isolated patients deny drug ingestion, i.e., antidepressant 
drugs (Case 2), herbal remedies, or other drugs.
3. The dilemma commonly faced is that some patients 
infrequently or simultaneously ingest various drugs; 
therefore, it is sometimes impossible to identify what 
drug(s) could have caused the hemolysis and drug testing is 
not possible, even when DIIHA is suggested. We are aware 
of several cases in which we were unable to identify the 
causative drug because of these factors.
4. Some patients, as well as physicians, automatically exclude 
long-term administered drugs that have not presented with 
prior signs of complications.
5. It is largely unknown that drug administration does not 
result in significant primary immunization within the 
first 5 days if the patient has not previously received the 
drug. Thereafter, immune reaction may occur at any time 
during continuous or intermittent administration or after 
reexposure of the causative drug.3
Pitfalls at Patient Bedside
The clue to correct diagnosis of DIIHA primarily remains 
in the hands of the primary physician. If this physician is 
not familiar with all aspects of acquired immune hemolytic 
anemias, this may then result in numerous errors.
1. Unfortunately, many physicians are not familiar with 
DIIHA. They are unaware that clinical manifestations 
and pictures are variable. Furthermore, there remains 
a lack of knowledge from a clinical or serologic 
viewpoint concerning the difference between DIIHA by 
Fig. 1 Numerous drugs found in the possession of a patient who 
died of drug-induced immune hemolytic anemia (Case 3).
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autoantibodies (aAbs) alone and that induced by drug-
dependent antibodies (ddAbs). These deficiencies are the 
reasons behind the various failures at the clinical bedside 
and in laboratories (see subsequent discussion).
2. Patients in addition to physicians seem to exclude drugs as 
a cause of acute reactions when they have been tolerated 
for a long time. Many physicians do, in fact, consider 
DIIHA in many patients with hemolysis. However, they 
seem to suspect, in general, only newly administered 
drugs. Most frequently, patients are asked whether they 
have altered their medications or received a new drug. 
Detailed information including drug history, onset and 
type of hemolysis, clinical picture, and course are rarely 
documented.
3. Inconclusive patient or drug history may lead to confusion 
with autoimmune hemolytic anemia (AIHA) of the warm 
type, particularly if the drug has led to the production of 
ddAbs or aAbs, leading to positive immunoglobulin G (IgG) 
DAT. Only a few drugs are known to cause the production 
of the latter antibodies alone (e.g., methyldopa, fludarabine), 
and some drugs have been reported to cause both types 
(e.g., diclofenac, cefotetan).4,5 It is unknown how many 
cases of warm AIHA are in fact not idiopathic but related to 
drugs. On physical examination, there are no characteristic 
findings of AIHA related to drugs. Autoantibodies induced 
by drugs are also serologically indistinguishable from 
“idiopathic” autoantibodies. Unfortunately, hemolysis 
related to drug-induced aAbs may persist for several weeks 
or even months after discontinuation of the causative 
drug. In such cases, recovery could be attributed to 
treatment rather than to stopping the drug. Thus, these 
cases remain unrecognizable as DIIHA.
4. On admission, almost all patients who exhibit immune 
hemolysis automatically receive high doses (at least 0.5–
1.0 mg/kg body weight) of steroids. In the case of DIIHA, 
an improvement caused by intentional or unintentional 
cessation of the causative drug might be attributed to 
treatment and not to discontinuation of the drug(s). The 
incidence of these cases remains obscure.
5. Confusion with acute hemolytic transfusion reactions is 
also relatively common. Some patients may receive drugs 
that cause acute hemolysis before or simultaneously with 
blood transfusion. In most of these cases, a hemolytic 
transfusion reaction (HTR) will primarily be suspected 
rather than DIIHA (Case 4). The correct diagnosis can 
only be established if laboratory testing does not confirm 
either HTR or AIHA. This result is supported by several 
reported2,6–11 and unreported cases.
6. A fatal failure is the administration of the causative drug 
during the hemolytic attack. This failure may occur as 
long as the true diagnosis is unclear or when true AIHA 
has been suggested. Most dangerous is when the main 
symptom of the underlying disease is similar to that of 
intravascular hemolysis. We were aware of some patients 
who received diclofenac because of chronic lumbar pain 
and were administered the drug again after development 
of acute lumbar pain related to massive intravascular 
hemolysis rather than to the chronic affliction.
7. Infrequently, only secondary symptoms of DIIHA may 
initially be significant, leading to misdiagnosis or no 
diagnosis at all. During observation, the causative drugs 
are often automatically ceased. If these patients do not 
exhibit complications, they may quickly recover and be 
discharged without a final diagnosis (see described cases).
Pitfalls in the Laboratory
Similar to the situation at the clinical bedside, many 
serologists are not well informed about all the serologic 
and clinical aspects of DIIHA. This makes correct testing 
and interpretation of serologic findings often impossible. 
Unfortunately, to date, there remain no standard tests or 
guidelines to confirm serologic findings by certified laboratories 
similar to those for blood cell antigens and antibodies. These 
deficiencies represent risks of pitfalls leading to false-positive 
and false-negative results, misdiagnosis, or no diagnosis.
false-Positive results
1. Use of enzyme-treated RBCs may result in nonspecific 
agglutination in the presence of abnormal patient’s 
serum but not in the presence of normal serum. Indeed, 
the samples are not identical, and in vitro–treated RBCs 
are sometimes more susceptible to patient’s serum 
samples than to normal serum samples. We have not 
observed a reaction between specific ddAbs and enzyme-
treated RBCs, and not with native cells. However, some 
investigators have found that the use of enzyme-treated 
RBCs can be important for enhancing the detection 
of ddAbs. In these cases, it is indispensable to use an 
appropriate negative control (saline instead of the drug; if 
both react similarly, then a ddAb is not present).
2. Use of in vitro–treated RBCs may result in nonspecific 
reactions (nonimmunologic protein adsorption) similar 
to those observed by using enzyme-treated RBCs. This 
phenomenon has been described for different drugs 
including β-lactamase inhibitors, platinum, and some 
cephalosporins.12
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false-negative results
Different reasons may lead to false-negative results.
1. Testing of other drugs but not the causative drug may 
occur in cases in which a number of drugs are suspected 
or when only an innocent drug is suspected (see described 
cases).
2. Some laboratories still use test systems requiring washing 
procedures. Because the vast majority of drugs do not 
bind tightly to RBCs, ddAbs may escape detection if the 
wash solution used does not contain the causative drug or 
metabolites (1 mg/mL).13
3. Some ddAbs recognize, in the presence of the drug, 
RBC antigens and do not react with cells lacking the 
corresponding antigen.14–17 This phenomenon must be 
considered by using different or pooled RBCs and, most 
importantly, the patient’s RBCs.
4. Some ddAbs react with RBCs only in the presence of 
drug metabolites and not with the native drug (Cases 1 
and 2). Because drug metabolites are usually not available 
or remain unknown, the use of ex vivo preparations, e.g., 
urine or serum from persons receiving the suspected 
drug, is obligatory in all suspected cases that demonstrate 
negative results in the presence of the native drug.14,15 In 
such cases, we recommend the use of different ex vivo 
preparations (urine from the patient and urine or serum 
from different persons taking the drug) to include rare or 
even private metabolites.
5. Some ddAbs may become, within a relatively short time, 
undetectable in the patient’s serum. Thus, in such cases, 
negative results do not exclude DIIHA. Unfortunately, 
there is little information regarding this aspect. However, 
we are aware of isolated cases in which the causative 
antibody became undetectable within a 2-week period 
or less of the event occurring, i.e., diclofenac-dependent 
antibodies and one iohexol-dependent antibody. Initially, 
these antibodies were detectable in the presence of the 
drug or its metabolites.
misdiagnosis
The most common misdiagnoses are as follows:
1. Warm AIHA in cases in which aAbs are detectable. In 
addition to the phenomenon that drugs may lead to the 
production of aAbs or ddAbs, some drugs also result in 
the production of both types in the same patient. Thus, 
the presence of aAbs does not exclude ddAbs. The latter 
antibodies must be suspected in all cases in which 
intravascular hemolysis abruptly develops. In all these 
cases, a C3d-positive DAT (with or without IgG) is a 
cardinal finding.3
2. Panagglutinating antibodies that may be attributed to 
cold agglutinins of high thermal amplitude, agglutinating 
IgM warm aAbs, unspecific reactions, or IgG warm 
aAbs, sometimes with specificity. This phenomenon is 
characteristic in many cases during the acute phase of 
hemolysis and when the drug and its metabolite are still 
present in the circulation.
3. Acute HTRs are primarily suspected in nearly all cases in 
which blood transfusion is administered before or during 
hemolysis.2,6–11 If serologic testing remains inconclusive, a 
misdiagnosis will result even when alloantibodies are not 
detectable.
4. Infrequently, toxic reactions might be suggested if ddAbs 
escape serologic testing, e.g., contrast media.18
no diagnosis
Some patients have a history of DIIHA but have not been 
investigated at the appropriate stage. We are aware of several 
cases in which DIIHA appears to have developed, but could 
not be excluded or proven.
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